Key Points
- Todd Alfred Carter sold 4,174 shares of Voyager on Feb. 24 at an average price of $3.76 for about $15,694, reducing his stake by 2.78% to 145,718 shares (≈$547,900).
- Voyager shares traded at $4.26 (up 0.6%) with a market cap of roughly $236.6M and a 52‑week range of $2.64–$5.55; analysts are mixed, with an average rating of "Moderate Buy" and an average price target of $13.75 despite some downgrades.
- Institutional activity stands out—EcoR1 Capital boosted its stake to 4,002,847 shares (adding 3,332,544 in Q4), and hedge funds collectively own about 48.03% of the company.
Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) insider Todd Alfred Carter sold 4,174 shares of the company's stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $3.76, for a total transaction of $15,694.24. Following the completion of the transaction, the insider owned 145,718 shares in the company, valued at approximately $547,899.68. This represents a 2.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Todd Alfred Carter also recently made the following trade(s):
- On Tuesday, February 10th, Todd Alfred Carter sold 3,525 shares of Voyager Therapeutics stock. The shares were sold at an average price of $3.85, for a total transaction of $13,571.25.
Voyager Therapeutics Stock Up 0.6%
NASDAQ:VYGR traded up $0.03 on Friday, reaching $4.26. 26,299 shares of the company's stock were exchanged, compared to its average volume of 581,896. The firm has a market capitalization of $236.58 million, a price-to-earnings ratio of -1.97 and a beta of 1.30. Voyager Therapeutics, Inc. has a 52-week low of $2.64 and a 52-week high of $5.55. The business has a fifty day moving average of $3.86 and a 200-day moving average of $4.11.
Wall Street Analyst Weigh In
Several research firms have commented on VYGR. HC Wainwright dropped their price target on shares of Voyager Therapeutics from $30.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, November 12th. Wall Street Zen cut Voyager Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 21st. Finally, Wedbush reaffirmed an "outperform" rating and issued a $8.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Voyager Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $13.75.
Check Out Our Latest Report on VYGR
Hedge Funds Weigh In On Voyager Therapeutics
Large investors have recently bought and sold shares of the business. EcoR1 Capital LLC lifted its holdings in Voyager Therapeutics by 497.2% during the 4th quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company's stock worth $15,731,000 after buying an additional 3,332,544 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Voyager Therapeutics by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company's stock valued at $15,178,000 after acquiring an additional 40,147 shares during the last quarter. Opaleye Management Inc. acquired a new stake in shares of Voyager Therapeutics during the 4th quarter worth about $4,704,000. Erste Asset Management GmbH lifted its stake in Voyager Therapeutics by 7.0% during the fourth quarter. Erste Asset Management GmbH now owns 1,195,141 shares of the company's stock worth $4,718,000 after purchasing an additional 78,348 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Voyager Therapeutics by 1.1% during the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company's stock worth $3,474,000 after purchasing an additional 11,929 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company's stock.
About Voyager Therapeutics
(
Get Free Report)
Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company's core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.
The firm's pipeline includes several AAV-based candidates in preclinical and early clinical development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
